KaloBios, Post-Shkreli, Vows 'Maniacal' Focus On R&D And Transparency

Two months after emerging from bankruptcy with a plan to get back on its feet, KaloBios has rid itself of its biggest distraction: Martin Shkreli, the so-called Pharma Bro who was ousted as CEO in December after he was arrested on securities fraud charges stemming from another company he was associated with, Retrophin. KaloBios Pharmaceuticals announced Monday that Shkreli sold all his shares of the company to other investors and he and his affiliates are restricted from having anything to do with the biotech for two years under the terms of an agreement struck in July.